| Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. (NCT00622479) | Bayer | 2008-05-01 |
| Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients (NCT00891475) | Kidney Cancer Research Bureau | 2008-05-01 |
| A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC (NCT00664326) | Bayer | 2008-04-30 |
| Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan (NCT01411423) | Bayer | 2008-04-18 |
| A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer. (NCT00678288) | Bayer | 2008-04-01 |
| Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program (NCT01412671) | Bayer | 2008-02-27 |
| Sorafenib Dose Escalation in Renal Cell Carcinoma (NCT00618982) | Bayer | 2008-02-01 |
| Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC) (NCT00569946) | Pfizer | 2007-12-12 |
| Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer (NCT00854620) | Stanford University | 2007-12-01 |
| Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI (NCT00537056) | Stanford University | 2007-10-01 |
| A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma (NCT00502307) | AVEO Pharmaceuticals, Inc. | 2007-10-01 |
| Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors (NCT00516672) | GlaxoSmithKline | 2007-09-10 |
| Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer (NCT00529802) | University of Chicago | 2007-09-01 |
| Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034 (NCT00478725) | GlaxoSmithKline | 2007-07-18 |
| Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC (NCT00522249) | The Methodist Hospital Research Institute | 2007-05-01 |
| Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma (NCT00422786) | Thallion Pharmaceuticals | 2007-03-01 |
| Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer (NCT00448149) | The Methodist Hospital Research Institute | 2006-12-01 |
| Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC (NCT00496301) | Spanish Oncology Genito-Urinary Group | 2006-11-01 |
| Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma (NCT00372853) | AstraZeneca | 2006-11-01 |
| Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma (NCT00389285) | ZymoGenetics | 2006-10-01 |
| Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer (NCT00440973) | The Methodist Hospital Research Institute | 2006-10-01 |
| A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients (NCT00363194) | GlaxoSmithKline | 2006-09-21 |
| Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer (NCT00338884) | Pfizer | 2006-09-01 |
| Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer (NCT00387764) | GlaxoSmithKline | 2006-09-01 |
| Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma (NCT00356460) | Genzyme, a Sanofi Company | 2006-09-01 |
| Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib (NCT00352859) | Bayer | 2006-08-01 |
| A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes (NCT00401583) | GlaxoSmithKline | 2006-07-28 |
| Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar (NCT00895674) | Bayer | 2006-07-01 |
| A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) (NCT00726323) | GlaxoSmithKline | 2006-06-30 |
| Study To Assess Long Term Safety Of Pazopanib (NCT00387205) | Novartis Pharmaceuticals | 2006-06-20 |
| Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer (NCT00445523) | The Methodist Hospital Research Institute | 2006-05-01 |
| Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma (NCT00334282) | GlaxoSmithKline | 2006-04-01 |
| Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer (NCT00282048) | Pfizer | 2006-03-01 |
| Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (NCT00698685) | University of Arizona | 2006-01-23 |
| Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC) (NCT00267748) | Pfizer | 2005-12-01 |
| Long-term Extension From RCC Phase II (11515) (NCT00586495) | Bayer | 2005-12-01 |
| Study of SU011248 in Patients With Advanced Kidney Cancer (NCT00254540) | Pfizer | 2005-12-01 |
| Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC) (NCT00586105) | Bayer | 2005-12-01 |
| Research Study for Patients With Metastatic Renal Cell Carcinoma (NCT00110344) | Bayer | 2005-11-01 |
| Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer (NCT00445042) | The Methodist Hospital Research Institute | 2005-11-01 |
| Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma (NCT00325507) | Oxford BioMedica | 2005-11-01 |
| GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma (NCT00244764) | GlaxoSmithKline | 2005-10-01 |
| An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma (NCT00492986) | Bayer | 2005-10-01 |
| ATN-161 in Advanced Renal Cell Cancer (NCT00131651) | Attenuon | 2005-08-01 |
| BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (NCT00117637) | Bayer | 2005-06-01 |
| Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma (NCT00111020) | Bayer | 2005-06-01 |
| Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer (NCT00446368) | The Methodist Hospital Research Institute | 2005-05-01 |
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma (NCT00523640) | University of Chicago | 2005-03-01 |
| Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma (NCT00256880) | GlaxoSmithKline | 2005-01-01 |
| SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma (NCT00089648) | Pfizer | 2004-12-01 |
| BAY43-9006 Phase II Study for Renal Cell Carcinoma (NCT00661375) | Bayer | 2004-11-01 |
| Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma (NCT00113529) | Pfizer | 2004-10-01 |
| Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients (NCT00158782) | GlaxoSmithKline | 2004-09-28 |
| Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma (NCT00095186) | Agennix | 2004-09-01 |
| A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer (NCT00083941) | Oxford BioMedica | 2004-08-01 |
| SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma (NCT00083889) | Pfizer | 2004-08-01 |
| Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 (NCT00106301) | Celgene | 2004-04-01 |
| A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. (NCT00077974) | Pfizer | 2004-02-01 |
| Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer (NCT00073307) | Bayer | 2003-11-01 |
| Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV) (NCT00065572) | AstraZeneca | 2003-08-01 |
| A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma (NCT00265135) | Centocor, Inc. | 2003-08-01 |
| Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (NCT00065468) | Pfizer | 2003-07-01 |
| A Research Study for Patients With Metastatic Renal Cell Carcinoma (NCT00106613) | Celgene | 2003-05-01 |
| Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma (NCT00073125) | Abbott | 2003-05-01 |
| Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer (NCT00050323) | Genzyme, a Sanofi Company | 2002-11-01 |
| Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer (NCT00079612) | Bayer | 2002-09-01 |
| PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) (NCT00043368) | Pfizer | 2002-09-01 |
| A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma (NCT00059735) | Eisai Inc. | 2002-05-01 |
| CPG 7909 in Patients Wih Stage IV Renal Cell Cancer (NCT00043407) | Pfizer | 2002-03-01 |
| Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma (NCT00044564) | Bayer | 2001-12-01 |
| Detection of Renal Malignancy of Complicated Renal Cysts (NCT01087060) | Seoul National University Hospital | 1997-01-01 |
| Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. (NCT00502034) | Gruppo Oncologico Italiano di Ricerca Clinica | 1994-07-01 |
| A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 (NCT00001383) | National Cancer Institute (NCI) | 1994-03-01 |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) (NCT02962804) | University of Kansas Medical Center | |
| Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer (NCT00134186) | Pharmacyclics LLC. | |